DK3630098T3 - Kombination af en 5-ht6-receptorantagonist og en acetylcholinsteraseinhibitor til anvendelse i behandlingen af alzheimers sygdom hos en patientsubpopulation som har apoe4-alleller - Google Patents

Kombination af en 5-ht6-receptorantagonist og en acetylcholinsteraseinhibitor til anvendelse i behandlingen af alzheimers sygdom hos en patientsubpopulation som har apoe4-alleller Download PDF

Info

Publication number
DK3630098T3
DK3630098T3 DK18726791.9T DK18726791T DK3630098T3 DK 3630098 T3 DK3630098 T3 DK 3630098T3 DK 18726791 T DK18726791 T DK 18726791T DK 3630098 T3 DK3630098 T3 DK 3630098T3
Authority
DK
Denmark
Prior art keywords
insteration
apoe4
acetylcholine
alzheimer
alloys
Prior art date
Application number
DK18726791.9T
Other languages
English (en)
Inventor
Kristian Windfeld
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck As filed Critical H Lundbeck As
Application granted granted Critical
Publication of DK3630098T3 publication Critical patent/DK3630098T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/4045Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK18726791.9T 2017-05-24 2018-05-22 Kombination af en 5-ht6-receptorantagonist og en acetylcholinsteraseinhibitor til anvendelse i behandlingen af alzheimers sygdom hos en patientsubpopulation som har apoe4-alleller DK3630098T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA201700313 2017-05-24
DKPA201700538 2017-09-29
PCT/EP2018/063402 WO2018215478A1 (en) 2017-05-24 2018-05-22 Combination of a 5-ht6 receptor antagonist and an acetylcholinesterase inhibitor for use in the treatment of alzheimer's disease in a patient subpopulation carrying apoe4 alleles

Publications (1)

Publication Number Publication Date
DK3630098T3 true DK3630098T3 (da) 2021-04-26

Family

ID=62235961

Family Applications (1)

Application Number Title Priority Date Filing Date
DK18726791.9T DK3630098T3 (da) 2017-05-24 2018-05-22 Kombination af en 5-ht6-receptorantagonist og en acetylcholinsteraseinhibitor til anvendelse i behandlingen af alzheimers sygdom hos en patientsubpopulation som har apoe4-alleller

Country Status (22)

Country Link
US (1) US11464759B2 (da)
EP (1) EP3630098B1 (da)
JP (1) JP7167065B2 (da)
KR (1) KR102676011B1 (da)
CN (1) CN111032038A (da)
AU (1) AU2018272883B2 (da)
BR (1) BR112019001145A2 (da)
CA (1) CA3063968A1 (da)
CY (1) CY1124282T1 (da)
DK (1) DK3630098T3 (da)
ES (1) ES2869128T3 (da)
HR (1) HRP20210634T1 (da)
HU (1) HUE053636T2 (da)
LT (1) LT3630098T (da)
MX (1) MX2019013912A (da)
PL (1) PL3630098T3 (da)
PT (1) PT3630098T (da)
RS (1) RS61704B1 (da)
SG (1) SG11201909895UA (da)
SI (1) SI3630098T1 (da)
WO (1) WO2018215478A1 (da)
ZA (1) ZA201907525B (da)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE372768T1 (de) 2001-03-29 2007-09-15 Lilly Co Eli N-(2-arylethyl) benzylamine als 5-ht6 rezeptor- antagoniste
PT1529116E (pt) * 2002-08-07 2009-09-10 Novartis Ag Métodos para o tratamento da demência com base no genótipo da apo e
WO2008143361A1 (en) 2007-05-22 2008-11-27 Otsuka Pharmaceutical Co., Ltd. A medicament comprising a carbostyril derivative and donepezil for treating alzheimer's disease
WO2009074607A1 (en) 2007-12-12 2009-06-18 Glaxo Group Limited Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline
RU2369600C1 (ru) * 2008-01-24 2009-10-10 Андрей Александрович Иващенко ЗАМЕЩЕННЫЕ 4-СУЛЬФОНИЛ-ПИРАЗОЛЫ И 3-СУЛЬФОНИЛ-ПИРАЗОЛО[1,5-a]ПИРИМИДИНЫ - АНТАГОНИСТЫ СЕРОТОНИНОВЫХ5-HT6 РЕЦЕПТОРОВ, АКТИВНЫЙ КОМПОНЕНТ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, ЛЕКАРСТВЕННОЕ СРЕДСТВО И СПОСОБЫ ИХ ПОЛУЧЕНИЯ
US8404711B2 (en) 2009-04-13 2013-03-26 Theravance, Inc. 5-HT4 receptor agonist compounds for treatment of cognitive disorders
WO2014165701A1 (en) 2013-04-03 2014-10-09 The University Of Utah Research Foundation Application of 5-ht6 receptor antagonists for the alleviation of cognitive deficits of down syndrome
JO3459B1 (ar) 2012-09-09 2020-07-05 H Lundbeck As تركيبات صيدلانية لعلاج مرض الزهايمر
JP2018519358A (ja) 2015-05-07 2018-07-19 アクソファント サイエンシーズ ゲーエムベーハーAxovant Sciences Gmbh 神経変性疾患を処置する方法
RU2742173C2 (ru) * 2016-04-26 2021-02-02 Х. Лундбекк А/C Применение ингибитора ацетилхолинэстеразы и идалопирдина для снижения риска падений у пациентов с болезнью паркинсона
US10864191B2 (en) * 2016-05-11 2020-12-15 H. Lundbeck A/S 5-HT6 receptor antagonists for use in the treatment of Alzheimer's disease with apathy as comorbidity

Also Published As

Publication number Publication date
CY1124282T1 (el) 2022-07-22
EP3630098B1 (en) 2021-03-24
SG11201909895UA (en) 2019-11-28
SI3630098T1 (sl) 2021-07-30
LT3630098T (lt) 2021-05-25
EP3630098A1 (en) 2020-04-08
HUE053636T2 (hu) 2021-07-28
RU2019135609A (ru) 2021-06-24
HRP20210634T1 (hr) 2021-05-28
JP7167065B2 (ja) 2022-11-08
AU2018272883B2 (en) 2024-02-15
KR102676011B1 (ko) 2024-06-17
US11464759B2 (en) 2022-10-11
MX2019013912A (es) 2020-01-21
US20180353477A1 (en) 2018-12-13
RS61704B1 (sr) 2021-05-31
AU2018272883A1 (en) 2019-11-14
WO2018215478A1 (en) 2018-11-29
CN111032038A (zh) 2020-04-17
PT3630098T (pt) 2021-04-21
BR112019001145A2 (pt) 2019-04-30
ES2869128T3 (es) 2021-10-25
KR20200007795A (ko) 2020-01-22
PL3630098T3 (pl) 2021-09-06
RU2019135609A3 (da) 2021-08-23
CA3063968A1 (en) 2018-11-29
JP2020520964A (ja) 2020-07-16
ZA201907525B (en) 2022-02-23

Similar Documents

Publication Publication Date Title
DK3119911T3 (da) Forbindelser til anvendelse til behandling af alzheimers sygdom hos apoe4+/+ patienter
MA45937A (fr) Inhibiteurs d'amino pyrimidine ssao
DK3134386T3 (da) Isoindolin-1-on-derivater med kolinerg muscarin-m1-receptor-positiv allosterisk modulatoraktivitet til behandling af alzheimers sygdom
DK3789501T3 (da) Fremgangsmåde til diagnosticering, behandling og forebyggelse af parkinsons sygdom
UY36153A (es) ?inhibidores de la fosfoinosítido 3-quinasa delta para su uso en el tratamiento de una enfermedad cutánea inmunoampollosa mediada por autoanticuerpos?
DK3436022T3 (da) Oxysteroler og fremgangsmåder til anvendelse heraf
MA52004A (fr) Inhibiteurs d'o-glycoprotéine-2-acétamido-2-désoxy-3-d-glycopyranosidase
DK3151851T3 (da) Ornithodoros-moubata-komplement-inhibitor til anvendelse i behandlingen af komplement-medierede sygdomme hos patienter med c5-polymorfisme
BR112017025998A2 (pt) inibidor de eixo igfbp3/tmem219, composição farmacêutica para uso no tratamento e/ou prevenção de diabetes, método para identificar um indivíduo em risco de desenvolver diabetes tipo 1 e/ou tipo 2 ou para monitorar a resposta a um tratamento terapêutico em um indivíduo e kit
DK3268374T3 (da) Kv1.3-inhibitorer og deres medicinske anvendelse
DK3448955T3 (da) Korrosionshæmmersammensætninger og fremgangsmåder til anvendelse deraf
DK3911304T3 (da) Tabletformuleringer med modificeret frigivelse indeholdende phosphodiesterase-hæmmere
MA54290A (fr) Inhibiteur de kinase aurora a destiné à être utilisé dans le traitement du neuroblastome
IT201900020576A1 (it) Manico per raspa e dispositivo chirurgico comprendente detto manico
MA50098A (fr) Procédés de détection du récepteur 1 des folates dans un échantillon provenant d'un patient
CL2019002808A1 (es) Métodos para prevenir o tratar enfermedades oftálmicas.
PH12018502703A1 (en) An oxazine derivative for use in the prevention of alzheimer's disease in at risk patients
FR3019031B1 (fr) Dispositif d'assistance a la mise en place d'un instrument orthopedique
MA49618A (fr) Inhibiteurs de la mpo destinés à être utilisés en médecine
DK3290525T3 (da) Fremgangsmåde til screening af lægemiddel og terapeutisk mål der anvendes til behandling af alzheimers sygdom
DK4061344T3 (da) 6-hydroxycannabidiol til anvendelse som lægemiddel
DK3630098T3 (da) Kombination af en 5-ht6-receptorantagonist og en acetylcholinsteraseinhibitor til anvendelse i behandlingen af alzheimers sygdom hos en patientsubpopulation som har apoe4-alleller
DK3049099T3 (da) Amyloid-beta-bindende peptider og anvendelse deraf til terapi og diagnosticering af alzheimers demens
DK3288949T3 (da) Tetrahydrofuran-fusionerede aminohydrothiazin-derivater, som er anvendelige inden for behandling af Alzheimers sygdom
MA52306A (fr) Agents préventifs et thérapeutiques de la sarcopénie